Eliquis Consolidated Litigation Almost Over(1)

Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.

By Martina Barash

Bristol-Myers Squibb Co. and Pfizer Inc. say consolidated proceedings over the blood thinner Eliquis are winding down, following rulings by the U.S. District Court for the Southern District of New York ( Fortner v. Bristol-Myers Squibb Co. , 2017 BL 259098, S.D.N.Y., No. 17cv1562 (DLC), 7/26/17 ).

The July 26 and 27 rulings echo the court’s decision in May that federal law blocked, or preempted, a similar case in the multidistrict litigation. The decision also said the drug’s warnings were legally adequate.

One case remains, Pfizer spokeswoman Allyanna Anglim said in an email July 28. The briefing deadline for the plaintiff in that case hasn’t passed yet, she said.

There were 69 actions total in the Eliquis litigation, according to a Judicial Panel on Multidistrict Litigation statistics report.

Eliquis belongs to a new class of blood thinners designed to be easier to use than older drugs, such as warfarin. However, unlike warfarin, some of the newer blood thinners have no reversal agent.

Attorneys for plaintiff Sheila Fortner couldn’t be reached for comment.

Salim-Beasley LLC represented plaintiff Sheila Fortner.

DLA Piper LLC (US) represented Bristol-Myers and Pfizer.

To contact the reporter on this story: Martina Barash in Washington at MBarash@bna.com

To contact the editor responsible for this story: Steven Patrick at spatrick@bna.com

For More Information

Full text at http://src.bna.com/re5.

Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.

Request Litigation on Bloomberg Law